December 1, 2017
Ayumi President Hikaru Ouchi Rheumatoid arthritis (RA) specialty firm Ayumi Pharmaceutical launched a biosimilar version of Remicade (infliximab) on November 29, making a foray into the Japanese biosimilar market. With two more RA biosimilars also in the wings, the company...read more